MedTrace Logo

Ultrasound Evaluation of Hematoma Risk After Needle EMG in Patient on DOAC Therapy

NCT07166302 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2025-09-10

No results posted yet for this study

Summary

Approximately 30 minutes after needle EMG, patients who are taking direct oral anticoagulants (DOACs) will undergo an ultrasound examination to evaluate for the presence of possible intramuscular hematomas at the muscles where the EMG needle was inserted. These hematomas are considered a potential adverse effect of needle EMG.

The aim of the study is to determine whether needle EMG can be considered a safe procedure in this group of patients, without posing a risk of intramuscular hematoma formation.

Conditions

  • Direct Acting Anticoagulant Adverse Reaction
  • Needle Injury
  • EMG
  • Peripheral Neuropathies
  • Mononeuropathies
  • Polyneuropathies
  • Neuromuscular Diseases (NMD)

Sponsors & Collaborators

  • University Hospital Brno

    collaborator UNKNOWN

  • Masaryk University

    lead OTHER

Principal Investigators

  • Eva Vlckova, MD · Masaryk University, University Hospital Brno

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-30
Primary Completion
2026-06-30
Completion
2026-12-31

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07166302 on ClinicalTrials.gov